Prospect of Natural Killer Cells in Cancer Immunotherapy

被引:0
作者
Meiliana, Anna [1 ,2 ]
Dewi, Nurrani Mustika [2 ]
Wijaya, Andi [1 ,2 ]
机构
[1] Padjadjaran State Univ, Postgrad Program Clin Pharm, Jl Eijkman 38, Bandung, Indonesia
[2] Prodia Clin Lab, Jl Cisangkuy 2, Bandung, Indonesia
关键词
NK-cells; NK-92; cells; immunotherapy; CAR;
D O I
10.18585/inabj.v10i3.532
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND: Current understanding in molecular character of natural killer (NK) cell, its function and mechanisms, send people the ideas to develop a NK-cell-based immunotherapeutic strategies against human cancer. CONTENT: Before being regards as a cell-based cellular therapy, NK cell have to be clinical proven. Early studies with NK cells infusions for acute myeloid leukemia and lung cancer showed a promising result. NK cells need simplified methods for enriching and expanding, in addition to its transfection with chimeric antigen receptors (CARs). NK-92 arise as an assuring effector cells to augment monoclonal and bispecific antibody therapy. Thus, NK cells show a potential opportunity for cell engineering, outstep the era of T cells. SUMMARY: It is believed that NK cells bring a bright hope for future cancer immunotherapies, either alone or in combination as a harmonious therapy.
引用
收藏
页码:192 / 202
页数:11
相关论文
共 107 条
[1]   2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells [J].
Altvater, Bianca ;
Landmeier, Silke ;
Pscherer, Sibylle ;
Temme, Jaane ;
Schweer, Katharina ;
Kailayangiri, Sareetha ;
Campana, Dario ;
Juergens, Heribert ;
Pule, Martin ;
Rossig, Claudia .
CLINICAL CANCER RESEARCH, 2009, 15 (15) :4857-4866
[2]   The key to unlocking CARs [J].
不详 .
NATURE BIOTECHNOLOGY, 2017, 35 (10) :889-889
[3]   Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].
Arai, S. ;
Meagher, R. ;
Swearingen, M. ;
Myint, H. ;
Rich, E. ;
Martinson, J. ;
Klingemann, H. .
CYTOTHERAPY, 2008, 10 (06) :625-632
[4]   Selection and expansion of natural killer cells for NK cell-based immunotherapy [J].
Becker, Petra S. A. ;
Suck, Garnet ;
Nowakowska, Paulina ;
Ullrich, Evelyn ;
Seifried, Erhard ;
Bader, Peter ;
Tonn, Torsten ;
Seidl, Christian .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (04) :477-484
[5]   Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells [J].
Berg, Maria ;
Lundqvist, Andreas ;
McCoy, Philip, Jr. ;
Samsel, Leigh ;
Fan, Yong ;
Tawab, Abdul ;
Childs, Richard .
CYTOTHERAPY, 2009, 11 (03) :341-355
[6]   THE CTLS KISS OF DEATH [J].
BERKE, G .
CELL, 1995, 81 (01) :9-12
[7]   Serial Killing of Tumor Cells by Human Natural Killer Cells - Enhancement by Therapeutic Antibodies [J].
Bhat, Rauf ;
Watzl, Carsten .
PLOS ONE, 2007, 2 (03)
[8]   Lymphocyte numbers and subsets in the human blood - Do they mirror the situation in all organs? [J].
Blum, Katrin S. ;
Pabst, Reinhard .
IMMUNOLOGY LETTERS, 2007, 108 (01) :45-51
[9]   Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells [J].
Boissel, Laurent ;
Tuncer, Hande H. ;
Betancur, Monica ;
Wolfberg, Adam ;
Klingemann, Hans .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) :1031-1038
[10]   Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells [J].
Boissel, Laurent ;
Betancura, Monica ;
Wels, Winfried S. ;
Tuncer, Hande ;
Klingemann, Hans .
LEUKEMIA RESEARCH, 2009, 33 (09) :1255-1259